Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Footer revision updated from v3.4.2 to v3.4.3. No visible changes to trial information or page behavior.
    Difference
    0.0%
    Check dated 2026-03-12T00:47:11.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the history. The government funding lapse notice and the prior Revision: v3.4.1 entry were removed.
    Difference
    0.3%
    Check dated 2026-02-11T12:47:03.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding and NIH operating status was added. The page revision was updated from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T06:51:56.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The history page now includes a glossary option, explains color-coding for additions (green) and deletions (red), and updates the revision banner to Revision: v3.4.0 (replacing v3.3.4).
    Difference
    0.4%
    Check dated 2026-01-28T06:19:41.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    New revision entry v3.3.4 was added and the previous revision v3.3.3 was removed in the Record History. This appears to be a routine system update to the page rather than a change to study information.
    Difference
    0.0%
    Check dated 2026-01-14T02:00:49.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Footer metadata updated to Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T09:42:59.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.